FIELD: biotechnology.
SUBSTANCE: antibodies are used as pharmaceutical means for treatment or prevention of inflammatory diseases.
EFFECT: invention enables to obtain antibodies with effective neutralising activity against NR10.
7 cl, 33 dwg, 19 tbl, 10 ex
Title | Year | Author | Number |
---|---|---|---|
NR10 ANTIBODY AND USING IT | 2008 |
|
RU2531521C2 |
ADVANCED ANTIBODY MOLECULES | 2009 |
|
RU2430111C1 |
PHARMACEUTICAL FORMULATION CONTAINING ADVANCED ANTIBODY MOLECULES | 2010 |
|
RU2565809C2 |
HUMAN INTERLEUKIN-13 ANTIBODIES AND THEIR APPLICATION | 2005 |
|
RU2427589C2 |
MODIFIED CONSTANT REGION OF ANTIBODY | 2008 |
|
RU2526512C2 |
MEDICINAL AGENT CONTAINING PHOSPHOLIPASE D4 ANTIBODY | 2014 |
|
RU2709741C2 |
IL-17 ANTAGONIST ANTIBODIES | 2005 |
|
RU2426741C2 |
ANTI-C5 ANTIBODIES AND THEIR USE | 2018 |
|
RU2774716C2 |
MEDICATION FOR TREATMENT OF LIVER CANCER | 2009 |
|
RU2523897C2 |
CYTOTOXICITY-INDUCING THERAPEUTIC AGENT | 2015 |
|
RU2812875C1 |
Authors
Dates
2013-07-10—Published
2009-12-04—Filed